Elutia Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Elutia wird ein Gewinn- und Umsatzwachstum von 33.6% bzw. 35.9% pro Jahr prognostiziert, während der Gewinn pro Aktie um 42.8% pro Jahr wachsen soll.

Wichtige Informationen

51.9%

Wachstumsrate der Gewinne

61.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.5%
Wachstumsrate der Einnahmen	40.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	18 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Elutia Inc.'s (NASDAQ:ELUT) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Jun 28

News Flash: 2 Analysts Think Elutia Inc. (NASDAQ:ELUT) Earnings Are Under Threat

Mar 10

Elutia Inc.'s (NASDAQ:ELUT) Share Price Is Matching Sentiment Around Its Revenues

Feb 21

Little Excitement Around Aziyo Biologics, Inc.'s (NASDAQ:AZYO) Revenues As Shares Take 63% Pounding

Apr 17

Aziyo Biologics appoints Williams as Chief Scientific Officer

Aug 26

Aziyo Biologics names co-founder C. Randal Mills as permanent CEO

Aug 10

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:ELUT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	72	-15	N/A	N/A	1
12/31/2025	37	-34	N/A	N/A	2
12/31/2024	27	-72	N/A	N/A	2
6/30/2024	25	-70	-21	-21	N/A
3/31/2024	25	-49	-19	-19	N/A
12/31/2023	25	-41	-22	-22	N/A
9/30/2023	25	-32	-18	-18	N/A
6/30/2023	25	-35	-19	-18	N/A
3/31/2023	19	-38	-20	-19	N/A
12/31/2022	24	-36	-22	-21	N/A
9/30/2022	28	-39	-23	-23	N/A
6/30/2022	34	-37	-21	-20	N/A
3/31/2022	46	-28	-18	-18	N/A
12/31/2021	47	-25	-16	-15	N/A
9/30/2021	49	-21	-15	-14	N/A
6/30/2021	49	-23	-13	-13	N/A
3/31/2021	46	-26	-16	-16	N/A
12/31/2020	43	-25	-14	-14	N/A
9/30/2020	42	-23	-12	-11	N/A
6/30/2020	42	-16	-12	-12	N/A
3/31/2020	43	-13	-10	-9	N/A
12/31/2019	43	-12	-8	-7	N/A
12/31/2018	39	-12	-6	-5	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ELUT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ELUT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ELUT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ELUTDie Einnahmen des Unternehmens (35.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: ELUTDie Einnahmen des Unternehmens (35.9% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ELUT in 3 Jahren voraussichtlich hoch sein wird

Elutia Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 71%

Price target increased by 60% to US$8.00

Consensus revenue estimates increase by 17%

Consensus revenue estimates increase by 12%, EPS downgraded

Consensus revenue estimates decrease by 25%, EPS upgraded

Price target decreased by 17% to US$10.00

Recent updates

Elutia Inc. Announces New Peer Reviewed Publication Highlighting the Robustness of Elupro™, Company’S Antibiotic-Eluting Bioenvelope for Implantable Devices

Consensus EPS estimates fall by 71%

New major risk - Financial position

New major risk - Share price stability

New minor risk - Market cap size

Chief Financial Officer exercised options to buy US$359k worth of stock.

Elutia Inc. to Report Q2, 2024 Results on Aug 07, 2024

Elutia Inc.'s (NASDAQ:ELUT) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

New major risk - Shareholder dilution

Price target increased by 60% to US$8.00

Elutia Inc. Announces FDA Clearance of EluPro®

Co-Founder exercised options and sold US$67k worth of stock

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Elutia Inc. to Report Q1, 2024 Results on May 09, 2024

New major risk - Shareholder dilution

Elutia Inc., Annual General Meeting, Jun 06, 2024

New major risk - Shareholder dilution

News Flash: 2 Analysts Think Elutia Inc. (NASDAQ:ELUT) Earnings Are Under Threat

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Elutia Inc. to Report Q4, 2023 Results on Mar 07, 2024

Elutia Inc.'s (NASDAQ:ELUT) Share Price Is Matching Sentiment Around Its Revenues

Elutia Submits CanGaroo Antibiotic-Eluting Biomatrix for FDA Clearance

Consensus revenue estimates increase by 17%

Elutia Notifies the Nasdaq Stock Market LLLC That the Company Was Not in Compliance with Listing Rule 5605(B)(1)

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

Berkeley Biologics, LLC completed the acquisition of Orthobiologics business unit of Elutia Inc. (NasdaqCM:ELUT).

Elutia Inc. Receives A Delisting Determination Letter from Listing Qualifications Department of Nasdaq

Elutia Inc. to Report Q3, 2023 Results on Nov 13, 2023

Elutia Inc. announced that it has received $10.5 million in funding from HighCape Partners Management, L.P., Nantahala Capital Management, LLC

New major risk - Shareholder dilution

Berkeley Biologics, LLC entered into an Asset Purchase Agreement Orthobiologics business unit of Elutia Inc. (NasdaqCM:ELUT) for $35 million.

Consensus revenue estimates increase by 12%, EPS downgraded

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Aziyo Biologics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Consensus revenue estimates decrease by 25%, EPS upgraded

Aziyo Biologics, Inc. Announces the Voluntary Recall of Its Viable Bone Matrix Products

Price target decreased by 17% to US$10.00

Aziyo Biologics, Inc. Presents Positive Clinical Data on Cangaroo® Biologic Envelope

First quarter 2023 earnings released: US$0.49 loss per share (vs US$0.60 loss in 1Q 2022)

Aziyo Biologics, Inc. to Report Q1, 2023 Results on May 10, 2023

Little Excitement Around Aziyo Biologics, Inc.'s (NASDAQ:AZYO) Revenues As Shares Take 63% Pounding

Full year 2022 earnings released

Aziyo Biologics, Inc. Provides Preliminary Sales Guidance for the Fourth Quarter and Full Year 2022

Aziyo Biologics, Inc. has completed a Follow-on Equity Offering in the amount of $11.1625 million.

Aziyo Biologics, Inc. has completed a Follow-on Equity Offering in the amount of $11.1625 million.

Aziyo Biologics, Inc. Revises Revenue Guidance for the Full Year 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Aziyo Biologics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Aziyo Biologics, Inc. Appoints David Colpman to Board of Directors and Audit Committee

Aziyo Biologics, Inc. Promotes Jeff Hamet to Senior Vice President of Finance

Aziyo Biologics, Inc. Appoints Michelle Leroux Williams, Ph.D as Chief Scientific Officer

Aziyo Biologics appoints Williams as Chief Scientific Officer

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aziyo Biologics, Inc. Announces Randal Mills as Chief Executive Officer

Aziyo Biologics names co-founder C. Randal Mills as permanent CEO

Aziyo Biologics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Aziyo Biologics, Inc. Appoints C. Randal (Randy) Mills, Ph.D. as Interim President

Aziyo Biologics Receives a Written Notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC Regarding Continued Listing Requirement Under Nasdaq Listing Rule 5450(b)(1)(A)

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aziyo Biologics, Inc. Confirms Financial Guidance for Year 2022

Price target decreased to US$13.00

Aziyo Biologics, Inc. to Report Q1, 2022 Results on May 09, 2022

Aziyo Biologics, Inc., Annual General Meeting, Jun 07, 2022

Aziyo Biologics, Inc. Announces FDA 510(k) Submission for CanGaroo® RM, its Next-Generation Biomaterial Envelope Enhanced with Antibiotics

Consensus EPS estimates fall by 10%

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum